GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Emcure Pharmaceuticals Ltd (NSE:EMCURE) » Definitions » EV-to-EBITDA

Emcure Pharmaceuticals (NSE:EMCURE) EV-to-EBITDA : 21.81 (As of Jun. 28, 2025)


View and export this data going back to 2024. Start your Free Trial

What is Emcure Pharmaceuticals EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Emcure Pharmaceuticals's enterprise value is ₹255,461 Mil. Emcure Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 was ₹11,715 Mil. Therefore, Emcure Pharmaceuticals's EV-to-EBITDA for today is 21.81.

The historical rank and industry rank for Emcure Pharmaceuticals's EV-to-EBITDA or its related term are showing as below:

NSE:EMCURE' s EV-to-EBITDA Range Over the Past 10 Years
Min: 12.26   Med: 18.96   Max: 29.31
Current: 21.81

During the past 5 years, the highest EV-to-EBITDA of Emcure Pharmaceuticals was 29.31. The lowest was 12.26. And the median was 18.96.

NSE:EMCURE's EV-to-EBITDA is ranked worse than
69.9% of 731 companies
in the Drug Manufacturers industry
Industry Median: 13.63 vs NSE:EMCURE: 21.81

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2025-06-28), Emcure Pharmaceuticals's stock price is ₹1299.80. Emcure Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 was ₹28.440. Therefore, Emcure Pharmaceuticals's PE Ratio (TTM) for today is 45.70.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).


Emcure Pharmaceuticals EV-to-EBITDA Historical Data

The historical data trend for Emcure Pharmaceuticals's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Emcure Pharmaceuticals EV-to-EBITDA Chart

Emcure Pharmaceuticals Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25
EV-to-EBITDA
- - - - 13.88

Emcure Pharmaceuticals Quarterly Data
Mar21 Mar22 Mar23 Sep23 Dec23 Mar24 Sep24 Dec24 Mar25
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only - - 27.41 24.93 13.88

Competitive Comparison of Emcure Pharmaceuticals's EV-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Emcure Pharmaceuticals's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Emcure Pharmaceuticals's EV-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Emcure Pharmaceuticals's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Emcure Pharmaceuticals's EV-to-EBITDA falls into.


;
;

Emcure Pharmaceuticals EV-to-EBITDA Calculation

Emcure Pharmaceuticals's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=255461.280/11715.05
=21.81

Emcure Pharmaceuticals's current Enterprise Value is ₹255,461 Mil.
Emcure Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹11,715 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Emcure Pharmaceuticals  (NSE:EMCURE) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Emcure Pharmaceuticals's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=1299.80/28.440
=45.70

Emcure Pharmaceuticals's share price for today is ₹1299.80.
Emcure Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹28.440.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?


Emcure Pharmaceuticals EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Emcure Pharmaceuticals's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Emcure Pharmaceuticals Business Description

Traded in Other Exchanges
Address
Plot No. P-1 and P-2, IT-BT Park, Phase II, M.I.D.C., Hinjawadi, Hinjawadi, MH, IND, 411057
Emcure Pharmaceuticals Ltd an Indian pharmaceutical company engaged in developing, manufacturing and globally marketing a range of pharmaceutical products across several therapeutic areas. Its portfolio includes orals including solids, liquid orals and dry syrup/suspensions., injectables such as vials and pre-filled syringes, and forms such as lyophilized & liquid and biotherapeutics.

Emcure Pharmaceuticals Headlines

No Headlines